• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:陈晨,李霞,董艳,王永静.1例临床药师参与伊马替尼与伏立康唑联合用药的药学监护[J].药学研究,2022,41(10):686-689[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2064次   下载 2155次 本文二维码信息
码上扫一扫!
1例临床药师参与伊马替尼与伏立康唑联合用药的药学监护
陈晨1,李霞2,董艳1,王永静3
字体:加大+|默认|缩小-
(1.山东大学第二医院临床药学科,山东 济南 250033;2.山东省药品不良反应监测中心,山东 济南 250014;3.山东大学第二医院血液内科,山东 济南 250033)
摘要:
目的 为伊马替尼与伏立康唑的联合用药提供药物用量调整思路。方法 对临床药师全程参与的1例费城染色体阳性的急性淋巴细胞白血病患者的治疗过程进行分析。该患者在伊马替尼治疗期间合并真菌感染,临床药师从药物的代谢特点、安全性等方面考虑,建议采用伏立康唑联合伊马替尼治疗,但需对伊马替尼进行剂量调整;结合患者病情将伊马替尼调整至每天0.2 g,后增加至每天0.3 g,并对伊马替尼进行血药浓度测定;联合用药期间评估和监测治疗过程中的药物不良反应。结果 医师采纳了临床药师的建议。采用伏立康唑联合伊马替尼联合用药期间,患者的感染得到了良好控制。伊马替尼血药浓度显示1 372.08 ng·mL-1,监测患者肝功能、血常规等正常,病情平稳。结论 临床药师参与了该患者的治疗过程,为其制订了个体化的治疗方案并取得了良好的效果,为伊马替尼与伏立康唑的联合用药提供药物用量调整思路。
关键词:  急性淋巴细胞白血病  伊马替尼  伏立康唑  临床药师  药学监护
DOI:10.13506/j.cnki.jpr.2022.10.012
基金项目:山东省药品化妆品不良反应监测哨点课题(No.2021SDADRKY04)
Pharmaceutical care of a patient with acute lymphoblastic leukemia in combination with imatinib and voriconazole
CHEN Chen1,LI Xia2,DONG Yan1,WANG Yongjing3
(1. Department of Clinical Pharmacy, the Second Hospital of Shandong University, Jinan 250033,China;2. Shandong Center for Adverse Drug Reaction Monitoring, Jinan 250014,China;3. Department of Hematology, the Second Hospital of Shandong University, Jinan 250033,China)
Abstract:
Objective To provide ideas for adjusting the dosage of imatinib and voriconazole in combination.Methods The treatment of 1 case of Philadelphia chromosome positive acute lymphoblastic leukemia participated by clinical pharmacists were analyzed. The patient was diagnosed for fungal infection during imatinib treatment. Considering the metabolic characteristics and safety of the drug, the clinical pharmacist recommended voriconazole combined with imatinib for treatment, but the dose of imatinib should be adjusted.The dose of imatinib was adjusted to 200 mg per day,and then increased to 300 mg per day.During the combination medication period, the blood concentration of imatinib was measured,and the adverse drug reactions were evaluated and monitored. Results Physicians adopted the recommendations of clinical pharmacists.During the combination therapy of voriconazole and imatinib, the patient's infection was well controlled. The blood concentration of imatinib showed 1372.08ng/mL, and the patient's liver function and blood routine were normal, and the condition was stable.the condition was stable. Conclusion The clinical pharmacist participated in the treatment process of this patient, formulated an individualized treatment plan and achieved good results, and provided ideas for the adjustment of drug dosage for the combination of imatinib and voriconazole.
Key words:  Acute lymphoblastic leukemia  Imatinib  Voriconazole  Clinical pharmacist  Pharmaceutical care
今日访问量:2495    总访问量:55338938
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司